Investors will have the opportunity to engage with 22 life sciences companies during the Life Sciences Virtual Investor Forum on June 24 and 25, 2026, co-hosted by Virtual Investor Conferences and Zacks Small-Cap Research, with B2i Digital, Inc. serving as the Official Marketing Partner. The event, a B2i Digital Featured Conference, provides a platform for clinical-stage biotechnology, rare-disease and oncology therapeutics, molecular diagnostics, medical devices, veterinary medicine, nutrition science, and AI-powered digital health companies to present and interact with investors.
B2i Digital brings the forum into its ecosystem, leveraging a distribution and media engine that drives qualified investors to presentations and one-on-one meetings. Before, during, and after the two days, B2i amplifies the event across its platform, putting these companies in front of a proprietary network of more than 1.7 million retail and institutional market participants. The same visibility engine has supported more than 115 investor conferences, reflecting the firm's approach of "From Marketing to Meetings℠."
Zacks Small-Cap Research, a preferred provider in the OTC Markets Group's Research Marketplace, prepares independent company-sponsored research and related content for distribution across investor and media channels. Its team of life sciences analysts supports the forum as co-host, adding credibility and depth to the event.
Each company has 30 minutes for a live presentation and Q&A session. One-on-one meeting requests are available through the VIC site, with replays posted on B2i Digital and OTC Markets YouTube channels. “Life sciences investors want efficient, direct access to management teams developing the therapies and technologies that matter, and pairing that access with independent research from Zacks makes the forum more valuable on both sides. Over two days, investors can meet companies across biotech, diagnostics, devices, and digital health, and reach their own conclusions,” said David Shapiro, Chief Executive Officer of B2i Digital.
The lineup includes Protalix BioTherapeutics, MetaVia Inc., CytoSorbents Corporation, PetVivo Holdings Inc., Jaguar Health, Inc., Reviva Pharmaceuticals Holdings, Inc., and 4DMedical Ltd. on Day One. Day Two features Prostatype Genomics AB, Abingdon Health plc, Innovotech, Inc., Lakewood-Amedex Biotherapeutics Inc., Nasus Pharma Ltd., Kelyniam Global, Inc., IMUNON, Inc., Promino Nutritional Sciences Inc., Envoy Medical Inc., Coiled Therapeutics plc, Aspire Biopharma Holdings Inc., Rocket Doctor AI Inc., Phio Pharmaceuticals Corp., aTyr Pharma, Inc., and NuFarm Ltd.
Throughout the year, Virtual Investor Conferences feature public companies from exchanges worldwide, including NYSE, Nasdaq, TSX, TSXV, CSE, ASX, LSE, and the OTC Markets. Virtual Investor Conferences is an OTC Markets Group Inc. property.
For registration and company profiles, visit the Virtual Investor Conferences website. To request one-on-one meetings with management, use the meeting request portal.
